Leonard Schleifer Net Worth

Leonard Schleifer has an estimated net worth of $2.9 billion, according to Forbes Real-Time Billionaires, Leonard Schleifer profile (figures as of October 20, 2026). That is up from $1.8 billion in 2019.

Leonard Schleifer is an American biotech executive best known for cofounded Regeneron Pharmaceuticals and still leading it as CEO. He started the company in 1988 with scientist George Yancopoulos after training in medicine and neurology. Regeneron went public in 1991 and grew into a major drugmaker based in Tarrytown, New York. Forbes places him in healthcare, and his wealth is tied mainly to Regeneron stock, where he owns 2% of the company’s common shares.

His career turned into a big money story through drug development. After early setbacks, Regeneron found a major winner with Eylea, approved in 2011 for age-related macular degeneration. The medicine became a blockbuster and helped make the company much larger. In 2024, U.S. sales of Eylea reached $4.8 billion. Regeneron has also built a broader business with 12 FDA-approved medicines, giving Schleifer a fortune Forbes estimated at $2.9 billion on October 20, 2026.

How Leonard Schleifer built his wealth

Schleifer’s fortune comes from the company he helped create. He cofounded Regeneron in 1988 and remains its CEO, giving him a long-running stake in the business as it grew from a young biotech firm into a major drugmaker. Regeneron went public in 1991, and Schleifer still owns 2% of its common stock. Because his wealth is tied to that equity, changes in Regeneron’s performance play a big role in Forbes estimates.

The business became much more valuable as Regeneron produced successful medicines. Its best-known moneymaker is Eylea, a treatment for macular degeneration that became the company’s first big commercial breakthrough after its 2011 approval. That drug alone brought in $4.8 billion in U.S. sales in 2024. Regeneron has also expanded beyond one product, with 12 FDA-approved medicines, which gives the company a broader base than a single-drug story.

What moved the Forbes estimate

Forbes has shown a sharp swing in Schleifer’s fortune over time. It estimated his net worth at $1.8 billion in 2019, then $1.2 billion in 2022. By 2024, Forbes put the figure at $3.5 billion. On Forbes’ real-time billionaires tracker, it stood at $2.9 billion as of October 20, 2026. Those moves fit a founder whose wealth is closely linked to the value of his shares in a public drug company.

The main business driver in the record here is Regeneron’s drug portfolio, especially Eylea. Strong sales from a blockbuster product can lift a company’s value, while dependence on market pricing means fortunes can rise and fall. Regeneron’s 12 FDA-approved medicines matter too, because they show the company is not built around only one launch. Forbes still ranked Schleifer among America’s self-made billionaires in healthcare in 2026, with a real-time estimate of $2.9 billion.